Prolonged effect of allergen sublingual immunotherapy to grass pollen
| Autor: | Agata Filipowska-Grońska, Marek Jąkalski, Andrzej Bozek, Jerzy Jarząb, Monika Jonska–Golus, Giorgio Walter Canonica |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Allergen immunotherapy medicine.medical_treatment Immunology medicine.disease_cause Immunoglobulin E 03 medical and health sciences 0302 clinical medicine Allergen Older patients immune system diseases Grass pollen otorhinolaryngologic diseases medicine Immunology and Allergy Sublingual immunotherapy Pharmacology biology business.industry Immunotherapy respiratory system respiratory tract diseases 030104 developmental biology 030228 respiratory system biology.protein business Research Paper |
| Zdroj: | Human vaccinesimmunotherapeutics. 14(12) |
| ISSN: | 2164-554X |
| Popis: | Background: The prolonged effect of allergen immunotherapy is unknown, especially in older patients. Objective: The three-year effect of sublingual allergen-specific immunotherapy (AIT) to grass pollen on elderly patients with allergic rhinitis was analyzed. Methods: Thirty-eight elderly patients (63.18 ± 3.12 yrs.) underwent AIT to grass pollen, were monitored for three years and were compared to a placebo group. AIT was performed with the use of an oral Staloral 300 SR grass extract (Stallergens Greer, London, UK) or a placebo. Symptoms and medication scores, represented by the average adjusted symptom score (AAdSS), the serum level of IgG4 to Phl p5 and the quality of life were assessed immediately after AIT and three years later. Results: After AIT, the AAdSS was significantly decreased and remained lower than in the placebo group during the three years after AIT. Serum-specific IgG4 against Phl p5 increased during the AIT trial in the study group. For the three years of observation after AIT, there were no significant changes in specific IgG4 levels against the analyzed allergens in comparison to the results immediately after AIT. The quality of life, based on the Rhinoconjunctivitis Quality of Life Questionnaire, was significantly decreased in patients who received AIT, from 1.83 (95%CI: 1.45–1.96) to 0.74 (95%CI: 0.39–1.92) (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|